Last reviewed · How we verify
Sanvar® (vapreotide)
Vapreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce symptoms in neuroendocrine tumors.
Vapreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce symptoms in neuroendocrine tumors. Used for Carcinoid syndrome associated with neuroendocrine tumors, Acromegaly (in selected cases).
At a glance
| Generic name | Sanvar® (vapreotide) |
|---|---|
| Sponsor | Debiovision |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vapreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and normal endocrine tissues. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, thereby reducing hormone-related symptoms and potentially slowing tumor growth. It is used primarily in the management of carcinoid syndrome and other neuroendocrine tumor-related complications.
Approved indications
- Carcinoid syndrome associated with neuroendocrine tumors
- Acromegaly (in selected cases)
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Injection site reactions
- Hyperglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |